Concept Companies and Lacerta Therapeutics, Inc. joined forces in a strategic collaboration that provides Lacerta with access to financial support for new expansions and facilities.
Concept Companies is a national real estate developer specializing in multiple asset classes, including technology and science, while Lacerta is a leader in the AAV gene therapy space.
The companies announced Lacerta’s new expansion of an 11,961-square-foot cGMP manufacturing facility in Alachua’s Progress District. Lacerta expects to create an additional 20 full-time jobs to support the clinical manufacturing of their AAV gene therapy products.
The projected completion of the new facility is in the company’s second quarter of 2023.
“The funding vehicle via Agility is indicative of the exceptional relationship between Concept Companies and Lacerta, and our strong commitment to the region,” said Dr. Edgar Rodriguez-Lebron, President/CEO of Lacerta Therapeutics, in a press release. “It also reflects the growth and success of Lacerta and the Alachua biotech hub. We are excited to join forces with Concept as we continue our mission to bring these much needed, novel medicines to the clinic.”
The new facility will have three large cGMP cleanroom suits, cleanroom support spaces, cGMP warehousing and storage, and additional offices and workstations.
The second building mainly focuses on manufacturing, complementing the company’s first building, which focuses on research and development.